Meeting
2023 ASCO Genitourinary Cancers Symposium
Limited relevance of the “very low risk” prostate cancer classification in the modern era: Results from a large institutional active surveillance cohort.
Authors
Kevin Shee
University of California, San Francisco, San Francisco, CA
Kevin Shee , Janet E. Cowan , Samuel L. Washington III, Hao G Nguyen , Katsuto Shinohara , Peter Carroll , Matthew R. Cooperberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 381)
DOI
10.1200/JCO.2023.41.6_suppl.381
Abstract #
381
Poster Bd #
N19
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
Performance of the 17-gene genomic prostate score test in men with prostate cancer (PCa) managed with active surveillance (AS): Results from the Canary Prostate Active Surveillance Study (PASS).
First Author: Daniel W. Lin
Poster
2019 Genitourinary Cancers Symposium
A 17-gene genomic prostate score as a predictor of adverse pathology for men on active surveillance.
First Author: Zachary Kornberg
Poster
2024 ASCO Genitourinary Cancers Symposium
A novel blood-based mRNA genomic test for screening, early detection, prognosis, and monitoring of prostate cancer: A multicenter study.
First Author: Yutaka Hashimoto
Poster
2024 ASCO Genitourinary Cancers Symposium
Safety and clinical validity of tumor genomic testing for guiding active surveillance selection in men with NCCN intermediate-risk prostate cancer.
First Author: Lauren Lenz